Cocrystal Pharma Inc
COCP
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.40 | 53.80 | -0.59% |
| CAC 40 | 8,156.23 | 100.72 | 1.25% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,790.52 | 421.89 | 0.89% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,696.41 | 47.35 | 0.18% |
| NASDAQ | 23,415.66 | 111.52 | -0.47% |
| Nikkei 225 | 50,842.93 | 68.83 | -0.14% |
| NZX 50 Index | 13,604.55 | 12.93 | -0.09% |
| S&P 500 | 6,835.67 | 3.24 | 0.05% |
| S&P/ASX 200 | 8,818.80 | 56.80 | -0.64% |
| SSE Composite Index | 4,002.76 | 15.84 | -0.39% |